BRIEF-Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million
Nov 10 (Reuters) - Voyager Therapeutics Q3 operating income USD -30.594 million.
- Q3 pretax profit USD -27.809 million
- Q3 net income USD -27.892 million
- Q3 basic EPS USD -0.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments